Table 3.
Overall limits of agreement between eGFR and mGFR
| Mean±SD | Wilcoxon test | Correlation analysis |
Bland-Altman analysis | ||||
|---|---|---|---|---|---|---|---|
| Z | P | r | P | Bias | 95%LOA | ||
| mGFR | 77.9±38.8 | - | - | - | - | - | - |
| Schwartz et al. (ScrEq09) | 83.4±48.5 | −1.476 | 0.14 | 0.77 | <0.001 | −5.5±26.0 | −56.5; 45.5 |
| Schwartz et al. (ScrEq12) | 71.2±30.7 | −2.229 | 0.03 | 0.77 | <0.001 | 5.7±20.0 | −33.5; 44.9 |
| Gao et al. | 76.4±36.8 | −1.490 | 0.14 | 0.73 | <0.001 | 1.5±50.0 | −96.5; 99.5 |
| Pottel et al. | 85.1±44.5 | −1.923 | 0.054 | 0.72 | <0.001 | −7.2±26.4 | −58.9; 44.5 |
| Hoster et al. | 84.9±46.2 | −2.281 | 0.02 | 0.78 | <0.001 | −7.0±24.1 | −54.2; 40.2 |
| Bokenkamp et al. | 126.5±64.0 | −7.573 | 0.00 | 0.81 | <0.001 | −48.7±40.4 | −127.9; 30.5 |
| Grubb et al. | 111.8±81.3 | −5.412 | 0.00 | 0.80 | <0.001 | −33.9±54.6 | −140.9; 73.1 |
| Filler et al. | 94.1±42.6 | −5.605 | 0.00 | 0.84 | <0.001 | −16.3±24.3 | −63.9; 31.3 |
| Schwartz et al. (ScysEq09) | 65.9±21.1 | −3.962 | 0.00 | 0.84 | <0.001 | 12.0±24. 6 | −36.2; 60.2 |
| Schwartz et al. (ScysEq12) | 71.2±27.0 | −1.937 | 0.053 | 0.84 | <0.001 | 6.6±22.5 | −37.5; 50.7 |
| Bouvet et al. | 73.9±31.1 | −0.506 | 0.61 | 0.73 | <0.001 | 3.9±28.3 | −51.6; 59.4 |
| Schwartz et al. (ScrcysEq09) | 77.9±32.3 | −0.445 | 0.66 | 0.87 | <0.001 | −0.0±16.5 | −32.3; 32.3 |
| Schwartz et al. (ScrcysEq12) | 76.2±30.8 | −0.186 | 0.85 | 0.88 | <0.001 | 1.7±16.6 | −30.8; 34.2 |
| Chehade et al. | 74.4±28.1 | −0.308 | 0.76 | 0.79 | <0.001 | 3.4±31.2 | −57.8; 64.6 |
Note: GFR unit is mL/min/1.73 m2; 95% LOA is the 95% limits of agreement; Z is the value of the Wilcoxon test between eGFR and mGFR; r is the Spearman’s Correlation Coefficient between eGFR and mGFR. The shaded rows are equations for which there is no significant difference between eGFR and mGFR in Wilcoxon test.